Michelle M. Mello's Testimony Before the U.S. House Committee on Energy and Commerce Health Subcommittee
In this testimony presented to the U.S. House Committee on Energy and Commerce’s Subcommittee on Health hearing titled “Examining Opportunities to Advance American Health Care through the Use of Artificial Intelligence Technologies,” Michelle M. Mello calls for policy changes that will promote effective integration of AI tools into healthcare by strengthening trust.
In collaboration with
Executive Summary
Although poorly designed regulation can hinder innovation, the government has a critical role to play in ensuring the conditions for innovation to translate into actual adoption of healthcare AI. In the U.S. market today, the key challenge isn’t stunted innovation — it’s low uptake of AI innovation. A major reason adoption lags behind innovation and interest in AI is a foundational trust deficit. There are four areas where experts agree policy changes could promote AI adoption by building confidence in its performance:
Ensure the entities that develop and use AI adequately assess, disclose, and mitigate the risks of these tools. Healthcare organizations and health insurers should be required to show they have an AI governance process in place that meets certain standards. AI developers should be required to document and disclose key pieces of information about their products’ design and performance.
Support independent research on how AI tools perform in practice. Such research can help healthcare organizations and insurers answer important questions about where investments in AI solutions can generate the greatest benefit and minimize potential risks. It also ensures that this knowledge is disseminated broadly.
Modify healthcare reimbursement policies to better support adoption and monitoring of effective AI tools. Many AI tools will not save healthcare organizations money, and monitoring them properly can be costly.
Address shortcomings in the Food and Drug Administration’s statutory framework to make the agency a more constructive partner in AI development and adoption. In some areas, the agency’s authority doesn’t go far enough; in others, it burdens developers with an antiquated regulatory framework that fails to anticipate the AI revolution.
A recording of Michelle M. Mello's testimony and the full committee hearing is available on YouTube.
Related Publications
Response to OSTP's Request for Information on Accelerating the American Scientific Enterprise
Stanford scholars respond to a federal RFI on scientific discovery, calling for the government to support a new “team science” academic research model for AI-enabled discovery.
Stanford scholars respond to a federal RFI on scientific discovery, calling for the government to support a new “team science” academic research model for AI-enabled discovery.
Response to FDA's Request for Comment on AI-Enabled Medical Devices
Stanford scholars respond to a federal RFC on evaluating AI-enabled medical devices, recommending policy interventions to help mitigate the harms of AI-powered chatbots used as therapists.
Stanford scholars respond to a federal RFC on evaluating AI-enabled medical devices, recommending policy interventions to help mitigate the harms of AI-powered chatbots used as therapists.
Russ Altman’s Testimony Before the U.S. Senate Committee on Health, Education, Labor, and Pensions
In this testimony presented to the U.S. Senate Committee on Health, Education, Labor, and Pensions hearing titled “AI’s Potential to Support Patients, Workers, Children, and Families,” Russ Altman highlights opportunities for congressional support to make AI applications for patient care and drug discovery stronger, safer, and human-centered.
In this testimony presented to the U.S. Senate Committee on Health, Education, Labor, and Pensions hearing titled “AI’s Potential to Support Patients, Workers, Children, and Families,” Russ Altman highlights opportunities for congressional support to make AI applications for patient care and drug discovery stronger, safer, and human-centered.
Increasing Fairness in Medicare Payment Algorithms
This brief introduces two algorithms that can promote fairer Medicare Advantage spending for minority populations.
This brief introduces two algorithms that can promote fairer Medicare Advantage spending for minority populations.